Analyst Reco. BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
82.44 ^USD	-1.62%		+1.89%	-14.50%

03/05	ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...
29/04	BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ANALYST RECOMMENDATIONS : Alphabet, Amgen, Starbucks, PayPal, Moderna...	03/05
Scotiabank Adjusts Price Target on BioMarin Pharmaceutical to $85 From $83, Maintains Sector Perform Rating	25/04	MT
Wells Fargo Adjusts Price Target on BioMarin Pharmaceutical to $110 From $100, Maintains Overweight Rating	25/04	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	16/04	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	02/04	MT
Wedbush Adjusts BioMarin Pharmaceutical's PT to $80 From $78, Keeps Neutral Rating; Continues to See Limited Upside	23/02	MT
BofA Securities Cuts BioMarin Pharmaceutical Price Target to $150 From $170, Maintains Buy Rating	26/01	MT
If you didn’t have enough signs, here’s more	15/11
ANALYST RECOMMENDATIONS : Datadog, Fair Isaac, HSBC, Home Depot, Wise...	15/11
BMO Capital Adjusts Price Target on BioMarin Pharmaceutical to $100 From $102, Keeps Outperform Rating	03/11	MT
UBS Trims BioMarin Pharmaceutical Price Target to $119 From $120, Maintains Buy Rating	02/11	MT
Barclays Cuts BioMarin Pharmaceutical's Price Target to $111 From $125, Overweight Rating Maintained	02/11	MT
Cantor Fitzgerald Adjusts Price Target on BioMarin Pharmaceutical to $100 From $120, Maintains Overweight Rating	02/11	MT
ANALYST RECOMMENDATIONS : Airbnb, Intel, CVS, Caterpillar, Qualcomm...	02/11
Morgan Stanley Cuts Price Target on BioMarin Pharmaceutical to $117 From $125, Keeps Overweight Rating	02/11	MT
Bernstein Upgrades BioMarin to Market Perform From Underperform, Price Target is $82	23/23/23	MT
ANALYST RECOMMENDATIONS : Amazon, Procter & Gamble, Salesforce, Unilever, Walgreens Boots...	23/23/23
ANALYST RECOMMENDATIONS : Amex, Biogen, Dollar General, Fortinet, Whitbread...	13/23/13
UBS Initiates Coverage on BioMarin Pharmaceutical With Buy Rating, $120 Price Target	18/23/18	MT
Wedbush Lifts BioMarin Pharmaceutical's PT to $78 From $71, Continues to See VOXZOGO/ACH as Main Driver of Growth; Keeps Neutral Rating	14/23/14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Analyst Reco.

Filters